Andrew C. Stone

Andrew C. Stone

Auto-generated profile, based on publicly available information

Andrew C. Stone

Department of Pharmacy, Wexner Medical Center, The Ohio State University, Columbus, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2021 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
ASAndrew C. Stone
Andrew C. Stone
KDKathleen Dungan
Kathleen Dungan
JGJoshua W. Gaborcik
Joshua W. Gaborcik

8 July 2026 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
YCYijie Cheng
Yijie Cheng
JGJoshua W. Gaborcik
Joshua W. Gaborcik
RSRachel M. Smith
Rachel M. Smith
KDKathleen Dungan
Kathleen Dungan
ASAndrew C. Stone
Andrew C. Stone
Background: Insulin is commonly used to manage steroid-induced hyperglycemia. However, optimal dosing strategies for long-acting steroids like dexamethasone remain unclear. Objectives: This study evaluated insulin glargine use for dexamethasone-induced hyperglycemia (DIH) and evaluated factors associated with achieving glucose targets (AGTs). Methods: This retrospective, single-centered cohort study included adult, noncritically ill patients who received once-daily insulin glargine and dexamethasone for at least 3 consecutive days during admissions between July 1, 2021, and July 31, 2023. Patients were excluded if they had type 1 diabetes mellitus or received intravenous insulin within the first 3 days. The primary outcome was the percentage of patients AGT, defined as mean blood glucose 70 to 180 mg/dL on day 3 of combination therapy. Patients were then stratified into AGT and persistent hyperglycemia (PH) cohorts to evaluate secondary outcomes which included hypoglycemia incidence and patient or treatment characteristics associated with AGT. Results: Among 118 patients included, 28 (24%) were in the AGT cohort and 90 (76%) were in the PH cohort. The AGT cohort had a lower mean body mass index (29.1 vs 33.7 kg/m 2 , P = .02) and fewer patients with preexisting type 2 diabetes mellitus (85.7% vs 97.8%, P = .03). Median insulin glargine units standardized by dexamethasone dose was similar between cohorts (2.25 [1.08-3.33] vs 2.00 [1.17-4.00] units/mg/day, P = .98). The PH cohort required significantly higher median daily bolus insulin doses (24 vs 6 units/day, P < .01). There was 1 patient, who was in the AGT cohort, who experienced hypoglycemia. Conclusion and Relevance: This study suggests that current practice underdoses insulin glargine initially for DIH management and relies on reactive bolus insulin with limited success. Earlier and more assertive insulin glargine dosing is warranted to improve early glycemic control without substantially increasing hypoglycemia risk. Limitations include the retrospective single-centered study design and limited sample size with imbalanced cohorts.

13 July 2013 in Sexually Transmitted Infections
Verified
Journal Article
Open access
PDF file
ZWZ Wu
Z Wu
BHB Young Holt
B Young Holt
JMJ Manning
J Manning
JRJ Romano
J Romano
MLM Lusti-Narasimhan
M Lusti-Narasimhan
BWB Wang
B Wang
Background In China, the HIV prevalence continues to rise despite increasing efforts to contain the epidemic, and other sexually transmitted infections (STIs) are also on the increase. Furthermore, antibiotic-resistant STI pathogens are on the increase and many STIs facilitate the acquisition and/or transmission of HIV-1. Multipurpose prevention technologies (MPTs), including drugs, devices and vaccines that simultaneously prevent unintended pregnancies, HIV and other STIs, would provide effective approaches to meet these public health challenges. Methods The Initiative for MPTs developed Target Product Profiles (TPPs) to define key product attributes appropriate for those regions of the world hardest hit by unintended pregnancy, HIV, and other STIs. The TPP considered priority combinations of indications, mechanisms of action, dosing and administration, and formulation and delivery. Current and historic data from China were reviewed to determine which product attributes in an MPT would best meet the needs in China. Results Sexual transmission of HIV-1 has become the major route for new infection in China, and other STIs have increased more than 40 times from 1985. The increase in STI rates is associated with population mobility, and the geographic distribution of STIs overlaps with that of HIV, suggesting the possibility of co-infection. The rate of unintended pregnancy is low in China, given the “one child” policy. After analysing the current and historic data, we propose that MPTs specifically addressing HIV and STIs would best meet the public health challenges in China, and the preferred dosing form would be long-acting implant or IUD-based delivery. Conclusion The continuing rise in prevalence and rates of STIs, including HIV poses serious public health challenges to China, where sustained economic development has resulted in social transformation and unprecedented population mobility. MPTs that specifically target HIV and other STIs could provide an effective approach to meeting these public health challenges in China.